Related search

Altered Androgen Receptor Activity Drives CHD1-Null Prostate Cancer

Cancer Discovery
Oncology
2019English

SPOP Promotes ATF2 Ubiquitination and Degradation to Suppress Prostate Cancer Progression

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2018English

SPOP Suppresses Prostate Cancer Through Regulation of CYCLIN E1 Stability

Cell Death and Differentiation
Cell BiologyMolecular Biology
2018English

Mp68-12 Impact of Spop Mutation on Prostate Cancer Prognosis

Journal of Urology
Urology
2019English

Aneuploidy Drives Lethal Progression in Prostate Cancer

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2019English

Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer

Clinical Medicine Insights: Urology
2013English

Structures of Cytochrome P450 17A1 With Prostate Cancer Drugs Abiraterone and TOK-001

Nature
Multidisciplinary
2012English

Abiraterone Acetate for Early Stage Metastatic Prostate Cancer: Patient Selection and Special Considerations

Therapeutics and Clinical Risk Management
2018English

Expanding the Use of Abiraterone in Prostate Cancer: Is Earlier Always Better?

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy